MedTrace Logo

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

NCT07383103 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2026-03-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Hydrocortisone plus Fludrocortisone

Hydrocortisone will be administered at a dose of 200 mg per day by continuous intravenous infusion. Fludrocortisone will be administered at a dose of 50 μg once daily orally or via nasogastric tube. Both drugs will be given for up to 7 days or until ICU discharge, whichever occurs first.

OTHER

Standard care

Patients will receive standard care for septic shock according to current international and institutional guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures. Fludrocortisone will not be administered.Hydrocortisone may be administered at the discretion of the treating physician.

Sponsors & Collaborators

  • Northern Jiangsu People's Hospital

    lead OTHER

Principal Investigators

  • Qingquan Lyu, Master · Northern Jiangsu People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07383103 on ClinicalTrials.gov